Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
Line Uhrenholt, Annette Schlemmer, Ellen-Margrethe Hauge, Robin Christensen, Lene Dreyer, Maria E Suarez-Almazor, Salome Kristensen
Dive into the research topics of 'Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)'. Together they form a unique fingerprint.